USA |OTCQB |USD
Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, focuses in the areas of non?alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188 (N,N-Dimethyltryptamine), a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.
|Public Float||P/E Ratio||-|
|% Short of Float||-||Dividend (Yield)||-|
|Held by Insiders||2.20%||Ex-Dividend Date|
|Held by Institutions||-||IPO Date||-|
|Aug 21||Aug 20||Aug 19|
|May 22||Feb 22||Nov 21|
Algernon pharmaceuticals trades on the OTC Markets stock market in USA under the ticker symbol "AGNPF". Algernon pharmaceuticals’s stock symbol can also be displayed as "OTCMKTS:AGNPF".
Algernon pharmaceuticals (OTCMKTS:AGNPF) is owned by 0.00% institutional shareholders and by 2.20% insiders. The rest is owned by the public.
Explore More Details on Algernon pharmaceuticals's “Ownership” Section
Algernon pharmaceuticals's key executive team includes the following managers:
Algernon pharmaceuticals (OTCMKTS:AGNPF) is classified under the "Healthcare" sector and under the "Biotechnology" industry.
Currently the number of employees working for Algernon pharmaceuticals is 0.
Algernon pharmaceuticals (OTCMKTS:AGNPF) is headquartered in BC, Canada.
Algernon pharmaceuticals’s mailing address is 700 West Pender Street, Vancouver, BC, Canada, V6C 1G8.
The company’s phone number is 604 398 4175.